Emerging Fungal Infections

Intro & Drivers - The Rising Tide

• Emerging Fungal Infections (EFIs): Infections newly appeared, rapidly ↑ incidence/geographic range, or evolved/drug-resistant.

• Global Health Threat: ↑ morbidity & mortality, esp. in immunocompromised.

• Key Drivers:

  • ↑ Immunocompromised populations (HIV, transplants, biologics)
  • Climate change & environmental factors
  • ↑ Use of broad-spectrum antifungals → resistance
  • International travel & trade
  • Improved diagnostic capabilities

⭐ Candida auris is a multi-drug resistant yeast that can cause invasive infections and is difficult to identify with standard laboratory methods, posing a significant nosocomial threat worldwide.

Key Pathogens - Fungal Foes

• Candida auris (C. auris)

  • Multidrug-resistant (MDR) yeast; causes healthcare-associated infections (HAIs), outbreaks.
  • Difficult to identify with standard lab methods; high mortality.
  • Transmission: Contact with contaminated surfaces or infected individuals.
  • 📌 Auris Usually Resists Infection Solutions.

• Cryptococcus gattii (C. gattii)

  • Infects immunocompetent individuals, unlike C. neoformans.
  • Associated with eucalyptus trees; causes pulmonary & CNS infections (cryptococcomas).
  • Requires prolonged treatment.

• Azole-Resistant Aspergillus fumigatus (ARAf)

  • Global threat; resistance via cyp51A mutations (e.g., TR₃₄/L98H).
  • Acquired environmentally (agricultural azoles) or in-host.
  • ↑ mortality in invasive aspergillosis (immunocompromised).
  • Susceptibility testing crucial.

⭐ Candida auris can persist on dry surfaces in healthcare settings for several weeks, contributing significantly to its transmission and outbreak potential, making stringent environmental disinfection critical for control.

Diagnosis - Fungal Fingerprints

• Microscopy: Rapid visualization (KOH, Calcofluor White, India Ink); provides initial morphological clues, guides further testing.
• Culture: Gold standard (SDA, specialized media); allows species identification, Antifungal Susceptibility Testing (AFST). Challenges: slow growth, some organisms are fastidious.
• Histopathology: Biopsy with special stains (PAS, GMS); confirms tissue invasion and shows fungal morphology in situ.
• Serology (Non-Culture Based):
  • (1,3)-β-D-Glucan (BDG): Broad pan-fungal marker (serum/CSF).
  • Specific Antigens: e.g., Galactomannan (Aspergillus), Cryptococcal Antigen (CrAg) (Cryptococcus).
• Molecular Methods: PCR (panfungal/species-specific), sequencing (e.g., ITS region); vital for rare, novel, or unculturable fungi.
• MALDI-TOF MS: Rapid proteomic identification from culture isolates; accuracy dependent on comprehensive databases.
• AFST: Essential for guiding appropriate therapy and monitoring emerging resistance patterns.

⭐ (1,3)-β-D-Glucan (BDG) is a key pan-fungal marker, but typically negative in Mucormycosis and may be low/negative in Cryptococcosis.

Management & Resistance - Battle Tactics

• Principles: Early diagnosis, source control, antifungal stewardship, immune support.
• Antifungals & Resistance:
  • Azoles (Vori, Posa, Isavu): Inhibit ergosterol synthesis. Resist: ERG11 mutation, efflux.
  • Echinocandins (Caspo, Mica): Inhibit glucan synthesis. Resist: FKS mutations.

    ⭐ Candida auris often shows multidrug resistance (MDR); susceptibility testing is crucial.

  • Polyenes (AmB): Bind ergosterol. Resist: Rare, ergosterol changes.
  • 5-FC: DNA/RNA inhibitor. Rapid solo resistance.
• Pathogen Tactics:
  • C. auris: Echinocandins first; L-AmB if resistant. Strict infection control.
  • Azole-R Aspergillus: L-AmB, Vori/Isavu (if susceptible).
  • Mucormycosis: Surgery + L-AmB (3-5 mg/kg/day, up to 10 mg/kg/day).
• Prevention: Prophylaxis (high-risk), surveillance, environmental hygiene. ​

High‑Yield Points - ⚡ Biggest Takeaways

• Candida auris: A multidrug-resistant (MDR) yeast causing nosocomial outbreaks; difficult to identify.
• Mucormycosis: Surged post-COVID-19, especially in uncontrolled diabetics; classic rhino-orbital-cerebral presentation.
• Cryptococcus gattii: Notably infects immunocompetent individuals, unlike C. neoformans.
• Azole-resistant Aspergillus fumigatus: A significant and emerging threat.
• Fusarium spp.: Cause fungal keratitis (contact lens use) and infections in the immunocompromised.
• Scedosporium spp.: Associated with near-drowning and often Amphotericin B resistant.